Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Equal-Weight rating on Apellis Pharmaceuticals (NASDAQ:APLS) but has lowered the price target from $47 to $43.
September 24, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo has maintained its Equal-Weight rating on Apellis Pharmaceuticals but reduced the price target from $47 to $43, indicating a more cautious outlook.
The lowering of the price target by Wells Fargo suggests a less optimistic view on Apellis Pharmaceuticals' future performance, which could lead to a negative short-term impact on the stock price. The Equal-Weight rating indicates a neutral stance, but the reduced price target reflects potential concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100